NasdaqGS - Delayed Quote USD

IDEXX Laboratories, Inc. (IDXX)

476.35 -1.44 (-0.30%)
At close: April 19 at 4:00 PM EDT
476.35 0.00 (0.00%)
After hours: April 19 at 4:20 PM EDT
Loading Chart for IDXX
DELL
  • Previous Close 477.79
  • Open 482.20
  • Bid 475.33 x 100
  • Ask 476.85 x 200
  • Day's Range 471.42 - 482.21
  • 52 Week Range 372.50 - 583.39
  • Volume 511,847
  • Avg. Volume 412,398
  • Market Cap (intraday) 39.563B
  • Beta (5Y Monthly) 1.26
  • PE Ratio (TTM) 47.40
  • EPS (TTM) 10.05
  • Earnings Date May 1, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 604.62

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

www.idexx.com

11,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: IDXX

Performance Overview: IDXX

Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

IDXX
14.18%
S&P 500
4.14%

1-Year Return

IDXX
1.20%
S&P 500
19.55%

3-Year Return

IDXX
10.96%
S&P 500
18.68%

5-Year Return

IDXX
118.02%
S&P 500
70.99%

Compare To: IDXX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: IDXX

Valuation Measures

As of 4/19/2024
  • Market Cap

    39.56B

  • Enterprise Value

    40.18B

  • Trailing P/E

    47.35

  • Forward P/E

    43.67

  • PEG Ratio (5yr expected)

    4.55

  • Price/Sales (ttm)

    10.93

  • Price/Book (mrq)

    26.65

  • Enterprise Value/Revenue

    10.97

  • Enterprise Value/EBITDA

    33.00

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    23.08%

  • Return on Assets (ttm)

    22.83%

  • Return on Equity (ttm)

    80.74%

  • Revenue (ttm)

    3.66B

  • Net Income Avi to Common (ttm)

    845.04M

  • Diluted EPS (ttm)

    10.05

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    453.93M

  • Total Debt/Equity (mrq)

    71.90%

  • Levered Free Cash Flow (ttm)

    693.69M

Research Analysis: IDXX

Analyst Price Targets

460.00
604.62 Average
476.35 Current
675.00 High
 

Fair Value

Overvalued
% Return
476.35 Current
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Earnings

Consensus EPS
 

Research Reports: IDXX

  • IDXX: Lowering target price to $514.00

    IDEXX LABORATORIES INC has an Investment Rating of HOLD; a target price of $514.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Neutral
    Price Target
     
  • IDXX: Lowering target price to $546.00

    IDEXX LABORATORIES INC has an Investment Rating of HOLD; a target price of $546.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Neutral
    Price Target
     
  • IDXX: Lowering target price to $548.00

    IDEXX LABORATORIES INC has an Investment Rating of HOLD; a target price of $548.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.

    Rating
    Neutral
    Price Target
     
  • Analyst Report: IDEXX Laboratories, Inc.

    Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 35% of its revenue from outside the United States.

    Rating
    Bearish
    Price Target
     

People Also Watch